$0.53
5.90% day before yesterday
Nasdaq, Jan 02, 10:18 pm CET
ISIN
US09077B1044
Symbol
BCAB

BioAtla Inc Stock price

$0.53
-0.25 31.46% 1M
+0.14 34.32% 6M
-0.03 5.90% YTD
-0.08 13.00% 1Y
-7.72 93.52% 3Y
-33.24 98.42% 5Y
-17.47 97.03% 10Y
-17.47 97.03% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.03 5.90%
ISIN
US09077B1044
Symbol
BCAB
Industry

Key metrics

Basic
Market capitalization
$31.5m
Enterprise Value
$23.2m
Net debt
positive
Cash
$8.3m
Shares outstanding
58.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
27.2%
Return on Equity
-489.1%
ROCE
1,450.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-29.5m | $-112.2m
EBIT
$-30.0m | $-74.5m
Net Income
$-30.7m | $-64.8m
Free Cash Flow
$-57.1m
Growth (TTM | estimate)
Revenue
-100.0% | -100.0%
EBITDA
65.4% | -53.7%
EBIT
65.2% | -0.7%
Net Income
62.5% | 7.2%
Free Cash Flow
32.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.5
FCF per Share
$-1.0
Short interest
8.4%
Employees
61
Rev per Employee
$180.0k
Show more

Is BioAtla Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

BioAtla Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a BioAtla Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a BioAtla Inc forecast:

Buy
86%
Hold
14%

Financial data from BioAtla Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 8.84 8.84
62% 62%
-
- Research and Development Expense 21 21
71% 71%
-
-29 -29
65% 65%
-
- Depreciation and Amortization 0.58 0.58
46% 46%
-
EBIT (Operating Income) EBIT -30 -30
65% 65%
-
Net Profit -31 -31
63% 63%
-

In millions USD.

Don't miss a Thing! We will send you all news about BioAtla Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioAtla Inc Stock News

Neutral
GlobeNewsWire
3 days ago
SAN DIEGO, Dec. 31, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, and GATC Health Corp. (GATC), a tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, today announced a S...
Neutral
GlobeNewsWire
about one month ago
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has entered into Pre-paid Advance Agreements with an affiliate of Yorkville Advisors Global (Yorkville) and funds managed by of A...
Neutral
Seeking Alpha
about 2 months ago
BioAtla, Inc. ( BCAB ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Jay Short - Co-Founder, CEO & Chairman Sheri Lydick - Chief Commercial Officer Eric Sievers - Chief Medical Officer Richard Waldron - Senior VP & CFO Conference Call Participants Julie Miller Yu He - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, everyone, and welcome to...
More BioAtla Inc News

Company Profile

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Head office United States
CEO Jay Short
Employees 61
Founded 2007
Website www.bioatla.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today